ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Trends in Biosimilar Market Access
A thought leadership article authored by Jenny Lee and Gene Chieh, investigating how biosimilars have gained momentum in a growing number of markets.
Biomarker-driven Landscape in Clinical Trials
An interview with Nicole Cowan covering the new biomarker-driven landscape in clinical trials and the nuances of drug-diagnostics co-development programs.
Social Media Outreach
ICON expert Gretchen Goller considers social media outreach's beneficial effect on patient connectivity to date in the October 2019 edition of PharmaVoice.
Making it Easier for the Site to Succeed
A thought leadership article authored by EB McLindon, discussing how making clinical research easier for the site can also make life easier for sponsors.
NASH Clinical Trials – An Outlook on Challenges and Advances
Andrew Roche discusses the challenges of delayed diagnosis, and under diagnosis, of NASH, the impact on NASH clinical trials, and important NASH endpoints being considered.
ICON to Offer At-Home Clinical Trials following Symphony Purchase
ICON boosts its hybrid clinical trial and site support services with the acquisition of Symphony Clinical Research, a provider of in-home and alternate site services.
Alzheimer’s in Clinical Trials – Is There a Way Out of Ongoing Failures?
A thought leadership article authored by Peter Schueler, exploring how the series of failures in Alzheimer’s disease research has provided insights into the disease pathology, study methodologies and - as a consequence – in the design of future development programmes for anti-Alzheimer medications.
Validating Value Data: AI & Outcomes
The application of AI and machine learning in establishing a treatment’s value proposition is still a relatively new concept in pharma. Learn more in this article.
Patient Voices in the Industry
Will Maier and Kelly Franchetti discuss orphan drugs and patients' role in clinical trials as demand in the market increases.
Can Digital Technologies and AI improve R&D productivity enough to restore ROI?
A thought leadership article authored by Tom O’Leary, exploring what can be done to help ensure return on investment in clinical trials.